– Generated LUMRYZ™ net product revenue of $77.5 million, a 55% increase compared to third quarter 2024 – – Approximately 3,400 patients on LUMRYZ as of September 30, 2025, a 48% increase compared to September 30, 2024 – – Announced global settlement of all litigation with Jazz Pharmaceuticals, Inc. (“Jazz”) – – Acquisition by Alkermes plc (“Alkermes”) expected to close in first quarter 2026 – DUBLIN, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company fo ...

Alkermes (NasdaqGS:ALKS) M&A Announcement October 22, 2025 08:00 AM ET Company ParticipantsSandra Coombs - SVP Investor Relations and Corporate AffairsJoshua Reid - CFOPaul Matisse - Managing Director and Head of Biotech ResearchRichard Pops - CEODouglas Tsao - Managing Director of Equity ResearchJoseph Tong - Equity Research AssociateUmer Raffat - Senior Managing DirectorConference Call ParticipantsNone - AnalystNone - AnalystJessicca Fye - Managing Director and Equity Research AnalystBen Burnett - Equity ...